Medimmune stops arthritis and psoriasis trials
Tuesday, 31 August, 2004
Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.
The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...